Ladenburg Thalmann Assumes Elicio Therapeutics at Buy, Announces Price Target of $12

Benzinga Newsdesk www.benzinga.com Positive 52.6%

Neg 0% Neu 0% Pos 52.6%

Ladenburg Thalmann analyst Kevin DeGeeter assumes Elicio Therapeutics (NASDAQ:ELTX) with a Buy rating and announces Price Target of $12.